360° SearchNetwork Hot Spots Trends Time Series

Polymerase

Type: Keyphrase

Name: Polymerase

First reported 12 hours ago - Updated 12 hours ago - 1 reports

Hepatitis C: A 21st Century Success Story (Op-Ed)

Dr. David Bernstein is chief of the Division of Hepatology / Center for Liver Disease at the North Shore Health Care System in Hempstead, N.Y., and a professor of medicine at Hofstra North Shore-LIJ School of Medicine. He contributed this article to LiveScience's ... [Published LiveScience.com - 12 hours ago]

Entities: Hepatitis C, Boceprevir, Telaprevir

First reported May 22 2013 - Updated May 22 2013 - 1 reports

David Baker

Oral drug 'to revolutionise' hep C treatment

A new oral interferon-free regimen could revolutionise the way hepatitis C is managed, a Sydney GP says.The antiviral sofosbuvir has been very effective in phase three trials, with recently reported viral clearance rates of 100%, said GP Dr David Baker ... [Published Australian Doctor - May 22 2013]

Entities: David Baker, Sofosbuvir, Drugs, Interferon, Hepatitis C

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Dumbbell-Shaped DNA Analytes Amplified by Polymerase Chain Reaction for Robust Single-Nucleotide Polymorphism Genotyping by Affinity Capillary Electrophoresis

A sample preparation method was developed for single-nucleotide polymorphism (SNP) genotyping based on hybridization between a single-stranded DNA (ssDNA) analyte and an allele-specific oligonucleotide (ASO) probe. When the SNP site is located in the ... [Published Analytical Chemistry - May 22 2013]

Entities: hybridisation, polymorphism, SNP Genotyping, Moiety, Polymerase

First reported May 20 2013 - Updated May 20 2013 - 1 reports

PharmaMar completes enrolment in Phase IIb ovarian cancer trial

PharmaMar, a biopharmaceutical subsidiary of Zeltia SA, has completed enrolment for the randomised Phase IIb trial in resistant/refractory ovarian cancer with PM01183 versus Topotecan. This open-label trial is designed to confirm PM01183's activity in ... [Published Individual.com - May 20 2013]

Entities: Ovarian Cancer, Phase IIb, Tumor, Orphan drug

First reported May 17 2013 - Updated May 17 2013 - 1 reports

AstraZeneca PLC

AstraZeneca moves 3 cancer compounds to Phase III development

AstraZeneca has enrolled its first patient into a Phase II clinical trial for moxetumomab pasudotox, which is a treatment for unresponsive or relapsed hairy cell leukaemia patients.Three of its cancer compounds are being moved forward to Phase III clinical ... [Published Labmate Online - May 17 2013]

Entities: AstraZeneca PLC, Phase III, Cancer, Olaparib

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Kinetic Characterization of Exonuclease-Deficient Staphylococcus aureus PolC, a C-family Replicative DNA Polymerase

by Indrajit Lahiri, Purba Mukherjee, Janice D. PataPolC is the C-family replicative polymerase in low G+C content Gram-positive bacteria. To date several structures of C-family polymerases have been reported, including a high resolution crystal structure ... [Published Elites TV - May 17 2013]

Entities: Polymerase, Staphylococcus Aureus, DNA Polymerase

First reported May 16 2013 - Updated May 16 2013 - 1 reports

AZ puts three targeted cancer drugs into Phase III

Having recently stressed that oncology is a core therapy area for its research, AstraZeneca is moving three of its cancer compounds into Phase III trials.First up, MedImmune, AstraZeneca’s biologics R&D arm, has enrolled the first patient in a late-stage ... [Published Pharma Times - May 16 2013]

Entities: Phase III, Cancer, AstraZeneca PLC, Olaparib

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Scien.net Publishes New Polymerase & Reductase Bibliography

The novel Natural Sciences Bibliographic Web Portal aims to provide comprehensive bibliographic information on the basic and applied life, earth and health sciences and has published over 184,800 references and 133,600 tags. Scien.net has now newly included ... [Published PRWeb - May 16 2013]

Entities: Polymerase, Enzyme, Ribonucleic Acid

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Structures of Coxsackievirus, Rhinovirus, and Poliovirus Polymerase Elongation Complexes Solved by Engineering RNA Mediated Crystal Contacts

by Peng Gong, Matthew G. Kortus, Jay C. Nix, Ralph E. Davis, Olve B. PeersenRNA-dependent RNA polymerases play a vital role in the growth of RNA viruses where they are responsible for genome replication, but do so with rather low fidelity that allows ... [Published Elites TV - May 09 2013]

Entities: RNA, Polymerase, Elongation, Poliovirus, Rhinovirus

First reported May 07 2013 - Updated May 07 2013 - 2 reports

All-oral Hep C race heats up as Abbvie receives "breakthrough" status

AbbVie joined BMS today in gaining Breakthrough Therapy designation for an investigational Hep C treatment. The three drug combo of ABT-450/r (protease inhibitor and ritonavir), ABT-267 (an NS5A inhibitor) and ABT-333 (a non-nucleoside polymerase inhibitor) ... [Published Medical Marketing And Media - May 07 2013]

Entities: AbbVie, Phase II, ritonavir, John Leonard

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

In Vitro Resistance to ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis

Reported by Jules LevinEASL 2013 April 28 Amsterdam EASL: - (04/27/13) median 4 to 4.5 log HCV RNA reductions were seen in this study presented in a poster at EASL. EASL: - (04/23/13) C Tan, H., Jekle, A., Kang, H., Moy, C., Deval, J., *Tigges, A., *Zhang, ... [Published National AIDS Treatment Advocacy Project - Apr 30 2013]

Entities: Polymerase, Nucleotide, In Vitro, Hepatitis

First reported Apr 27 2013 - Updated Apr 27 2013 - 2 reports

3 Healthcare Stock Stories for Weekend Wellness

Avanir Pharmaceuticals ( NASDAQ: AVNR ): Closing price $3.29Avanir announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and ... [Published Wall St. Cheat Sheet - Apr 27 2013]

Entities: CareFusion Corp, Health Care, Quinidine Sulfate, NUEDEXTA

Quotes

Yet other sequencing methods are disclosed, e g., in U S Pat. No. 5,580,732 entitled "Method of DNA Sequencing Employing A Mixed DNA-Polymer Chain Probe" and U S Pat. No. 5,571,676 entitled "Method For Mismatch-Directed In Vitro DNA Sequencing."

Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - 5 hours ago]

"Pancreatic cancer treatment remains a difficult challenge. One approach has been to find subpopulations of tumors with biomarkers and to develop a more personalized approach to therapy,” James Farrell, MD, Director of Yale University Center for Pancreas Diseases, told dailyRx News."

Personalizing Pancreatic Cancer Treatment [Published Daily Rx - 7 hours ago]

"In the mammalian genome, 60-80% of relatively infrequent (1 per 100 bp on average) CpG dinucleotides are methylated at the carbon 5 position (1). In contrast, dense clusters of unmethylated CpG sequences (.about.1 per 10 bp) are found at the transcription start sites of genes (2). In certain circumstances, these CpG islands are heavily methylated with the concomitant silencing of the promoter and the silencing of gene activity (3). These modifications are considered to be important for development (4), genomic imprinting (5), and X chromosome inactivation through gene silencing (6, 7). Aberrant DNADNA methylation of CpG islands has been frequently observed in cancer cells (8)."

Patent Application Titled "Method for Enriching Methylated C. . . [Published Equities.com - 14 hours ago]

More Content

sort by: Date \| Relevance
Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - 5 hours ago]
Personalizing Pancreatic Cancer Treatment [Published Daily Rx - 7 hours ago]
Control of Translation and miRNA-Dependent Repr... [Published PLoS Biology - 9 hours ago]
Hepatitis C: A 21st Century Success Story (Op-Ed) [Published LiveScience.com - 12 hours ago]
BioMarin Gains on Prospects for Experimental Ca... [Published Bloomberg - 13 hours ago]
Patent Application Titled "Method for Enriching... [Published Equities.com - 14 hours ago]
New Keratitis Data Have Been Reported by Invest... [Published Equities.com - 16 hours ago]
Robust Site-Directed Mutagenesis Kit Enables St... [Published Biotech Daily - 17 hours ago]
Use of Allosteric Targets in the Discovery of S... [Published Sexual Development - 22 hours ago]
Oral drug 'to revolutionise' hep C treatment [Published Australian Doctor - May 22 2013]
Dumbbell-Shaped DNA Analytes Amplified by Poly... [Published Analytical Chemistry - May 22 2013]
Therapeutic use of anti-CS1 antibodies [Published PharmCast - May 22 2013]
Site-Directed Mutagenesis via Gibson Assembly [Published Drug Discovery and Development - May 21 2013]
AstraZeneca Provides Update on Oncology Pipeline [Published Pharmaceutical Technology - May 21 2013]
Primary efficacy and safety findings from phase... [Published NASDAQ OMX - May 21 2013]
Medivir: Primary efficacy and safety findings f... [Published Business Wire - May 21 2013]
Positive results from a phase Ia study with MIV... [Published GlobeNewswire - May 21 2013]
Positive results from a phase Ia study with MIV... [Published NASDAQ OMX - May 21 2013]
PharmaMar completes enrolment in Phase IIb ovar... [Published Individual.com - May 20 2013]
Identification of the Causative Gene for Simmen... [Published Elites TV - May 17 2013]
AstraZeneca moves 3 cancer compounds to Phase I... [Published Labmate Online - May 17 2013]
AbbVie receives breakthrough therapy designatio... [Published Zecco - May 17 2013]
Kinetic Characterization of Exonuclease-Deficie... [Published Elites TV - May 17 2013]
Current and Future Therapies for Hepatitis C Vi... [Published National AIDS Treatment Advocacy Project - May 17 2013]
Vascular Files Patent Infringement Complaint Ag... [Published BioMedReports - May 17 2013]
AZ puts three targeted cancer drugs into Phase III [Published Pharma Times - May 16 2013]
Chimerix's CMX001 Resistance Data Presented at ... [Published Yahoo! Finance - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Yahoo! Finance - May 16 2013]
TESARO Announces Presentation of Niraparib Clin... [Published Morningstar.com - May 16 2013]
Chimerix's CMX001 Resistance Data Presented at ... [Published Morningstar.com - May 16 2013]

Blogs

sort by: Date \| Relevance
H7N9: From anxiety to preparedness [Published H5N1 - May 13 2013] Many thanks to Greg Folkers for sending the link to this just-published opinion piece in Annals of Internal Medicine: Influenza A(H7N9): From Anxiety to Preparedness. It deals with two questions: Should we be concerned? And are we fully prepared for a ...
Single gene swap helps H5N1 switch hosts [Published H5N1 - May 02 2013] Via ScienceNow, a report by Martin Enserink discussing work done by Chen Hualan of Harbin Veterinary Research Institute in China: Single Gene Swap Helps Bird Flu Virus Switch Hosts. Click through for the full report and many links. Excerpt:Instead of ...
The origin, evolution, and functional impact of... [Published Genome Research current issue - May 01 2013] Short insertions and deletions (indels) are the second most abundant form of human genetic variation, but our understanding of their origins and functional effects lags behind that of other types of variants. Using population-scale sequencing, we have ...
Combination Drugs are the Future of the Europea... [Published Pharma-Mag - Apr 30 2013] Benefits include improved drug efficiency, reduced pill burden, and lower dosage frequency. The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved ...
3 Healthcare Stock Stories for Weekend Wellness [Published Wall St. Cheat Sheet - Apr 27 2013] Avanir Pharmaceuticals ( NASDAQ: AVNR ): Closing price $3.29Avanir announced Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Nuedexta (dextromethorphan hydrobromide and ...

Press Releases

sort by: Date \| Relevance
Medivir: Primary efficacy and safety findings f... [Published Business Wire - May 21 2013]
Transgene Presents Promising Pre-Clinical Data ... [Published Business Wire - Apr 29 2013]
Ligand Presents Preclinical Data on HepDirect™ ... [Published Business Wire Health News - Apr 26 2013]
SCYNEXIS Presents SCY-635 Data on HCV at Intern... [Published Business Wire - Apr 25 2013]
Annual Report 2012 [Published GlobeNewswire: Acquisitions News - Apr 04 2013]